These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
110 related articles for article (PubMed ID: 10125703)
41. Drug information resources for health professionals and consumers. Durkin C Natl Netw; 1998 Feb; 22(3):10-1. PubMed ID: 10176590 [No Abstract] [Full Text] [Related]
42. Computerized information systems used by the PMA. Cleveland CB; Marsh P Drug Inf J; 1975; 9(2-3):138-41. PubMed ID: 10297123 [No Abstract] [Full Text] [Related]
43. Report raises questions about drug companies advertising budgets. AIDS Policy Law; 1999 Aug; 14(14):1, 6. PubMed ID: 11366996 [TBL] [Abstract][Full Text] [Related]
44. Drug Information Association membership directory, 1974-1975. Drug Inf J; 1975; 9(1):36 pages between p. 26 and p. 27. PubMed ID: 10297120 [No Abstract] [Full Text] [Related]
45. The overdosage and/or poisoning information gap. Bolger PB; Shimomura SK; Cupit GC; Davis LJ; McCart GM J Clin Pharmacol; 1979; 19(2-3):160-4. PubMed ID: 422740 [TBL] [Abstract][Full Text] [Related]
46. Pharmaceutical manufacturers seek OIG comfort. Becker S Health Care Law Mon; 2002 Aug; ():3-6. PubMed ID: 12420396 [No Abstract] [Full Text] [Related]
47. Update and correction on drug-information center directory. Rosenberg JM Am J Hosp Pharm; 1982 Jul; 39(7):1157. PubMed ID: 7051821 [No Abstract] [Full Text] [Related]
48. [Pharmaceutical consultants don't give neutral information]. Reseland S Tidsskr Nor Laegeforen; 2008 Nov; 128(22):2620. PubMed ID: 19023368 [No Abstract] [Full Text] [Related]
49. Direct-to-consumer prescription drug advertising. Terzian TV Am J Law Med; 1999; 25(1):149-67. PubMed ID: 10207573 [No Abstract] [Full Text] [Related]
51. So much time for so little: Italy's pharmaceutical industry and doctors' information needs. Maestri E; Furlani G; Suzzi F; Campomori A; Formoso G; Magrini N BMJ; 2000 Jan; 320(7226):55-6. PubMed ID: 10617540 [No Abstract] [Full Text] [Related]
52. The potential for self-interested behavior by pharmaceutical manufacturers through vertical integration with pharmacy benefit managers: the need for a new regulatory approach. Mitchell EL Food Drug Law J; 1999; 54(1):151-83. PubMed ID: 11758556 [No Abstract] [Full Text] [Related]
53. Oral solid dosage forms that should not be crushed: 1994 revision. Mitchell JF; Pawlicki KS Hosp Pharm; 1994 Jul; 29(7):666-8, 670-5. PubMed ID: 10135147 [TBL] [Abstract][Full Text] [Related]
54. Ethics, profit and patients: when pharmaceutical companies sponsor medical meetings. Barton L J Hosp Mark; 1993; 8(1):71-82. PubMed ID: 10135504 [TBL] [Abstract][Full Text] [Related]
55. The delivery of health information. The role of industry in patient education. Denison GW Vital Speeches Day; 1983 Jan; 49(7):208-10. PubMed ID: 10258481 [No Abstract] [Full Text] [Related]
56. [Physicians report verbal drug information. Cases scrutinized by the IGM]. Perman E Lakartidningen; 2004 Aug; 101(35):2648, 2650. PubMed ID: 15458219 [No Abstract] [Full Text] [Related]
60. The US drug safety system: role of the pharmaceutical industry. Gibson BR; Suh R; Tilson H Pharmacoepidemiol Drug Saf; 2008 Feb; 17(2):110-4. PubMed ID: 17724741 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]